Infective endocarditis is an infection of the endocardial surface of the heart including infections of the large thoracic vessels and intracardiac foreign bodies characterized by the presence of vegetation which is a nidus for microorganism invasion.
Native valve endocarditis is an endovascular microbial infection of native heart valves that may be local including valvular and perivalvular destruction or distal due to detachment of septic vegetations with embolism, metastatic infection and septicemia.
Prosthetic valve endocarditis is an endovascular microbial infection of prosthetic heart valves and may be classified as an infection likely to have been acquired perioperatively and thus being nosocomial or likely to have been community-acquired.
Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.